Carregant...
Treating EGFR mutation resistance in non-small cell lung cancer – role of osimertinib
The discovery of mutations in EGFR significantly changed the treatment paradigm of patients with EGFR-mutant non-small cell lung cancer (NSCLC), a particular group of patients with different clinical characteristics and outcome to EGFR-wild-type patients. In these patients, the treatment of choice a...
Guardat en:
| Publicat a: | Appl Clin Genet |
|---|---|
| Autors principals: | , |
| Format: | Artigo |
| Idioma: | Inglês |
| Publicat: |
Dove Medical Press
2017
|
| Matèries: | |
| Accés en línia: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5536882/ https://ncbi.nlm.nih.gov/pubmed/28794650 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/TACG.S103471 |
| Etiquetes: |
Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!
|